Craig Hallum Issues Positive Forecast for DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) had its target price increased by equities researchers at Craig Hallum from $8.00 to $11.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Craig Hallum's price objective points to a potential upside of 180.68% from the company's current price.

Separately, HC Wainwright raised their price objective on shares of DiaMedica Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Friday.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC traded down $0.01 during mid-day trading on Friday, reaching $3.92. The company had a trading volume of 250,561 shares, compared to its average volume of 109,114. The stock has a fifty day moving average of $3.92 and a two-hundred day moving average of $4.70. The company has a market capitalization of $168.05 million, a price-to-earnings ratio of -6.13 and a beta of 1.17. DiaMedica Therapeutics has a 12-month low of $3.19 and a 12-month high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, meeting the consensus estimate of ($0.18). During the same quarter in the prior year, the business posted ($0.14) EPS. Sell-side analysts forecast that DiaMedica Therapeutics will post -0.59 earnings per share for the current fiscal year.

Institutional Trading of DiaMedica Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DMAC. Bank of Montreal Can acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter worth about $84,000. Cornerstone Wealth Management LLC acquired a new position in DiaMedica Therapeutics during the 1st quarter worth approximately $62,000. Raymond James Financial Inc. acquired a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $83,000. Millennium Management LLC boosted its position in DiaMedica Therapeutics by 151.8% during the 4th quarter. Millennium Management LLC now owns 84,829 shares of the company's stock worth $461,000 after acquiring an additional 51,139 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in DiaMedica Therapeutics during the 4th quarter worth approximately $229,000. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.